Cann Global Ltd
ASX:CGB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (15.5), the stock would be worth AU$-0.16 (853% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.1 | AU$0.02 |
0%
|
| Industry Average | 15.5 | AU$-0.16 |
-853%
|
| Country Average | 13.2 | AU$-0.13 |
-742%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Cann Global Ltd
ASX:CGB
|
5.4m AUD | -2.1 | -0.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 49 | 39.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
542.6B USD | 22.6 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.7B GBP | 19.5 | 27.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 14.3 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 16.8 | 15.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.9 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 13 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 8.3 | 16.7 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.9 |
| Median | 13.2 |
| 70th Percentile | 19.2 |
| Max | 8 864.3 |
Other Multiples
Cann Global Ltd
Glance View
Cann Global Ltd. engages in the mining exploration and evaluation. The company is headquartered in Sydney, New South Wales. The company went IPO on 2008-01-14. The Company’s divisions include Food, Hemp Cultivation, and Processing, Skincare, Medicine, and Mining division. The Food division is focused on the production and distribution of healthy and nutritious plant-based food products for discerning Australian and Asian consumers. Hemp Cultivation and Processing division includes hulling in Australia, and broad-acre industrial cannabidiol (CBD) hemp cultivation and processing in Asia where growing conditions are ideal. The Skincare division, which includes oil, serum, and a cream product all contain hemp seed oil as the primary active ingredient. The Medicine division is responsible for research into the medicinal uses of cannabis, including research into the benefits for those with auto-immune diseases. The Mining division holds bauxite assets in the South Johnstone project, Queensland (EPM 18463).
